Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A15 | Q9H2J7 | 14/20 | 0.61 |
| ▸ | HRH1 | P35367 | 11/20 | 0.61 |
| ▸ | MEN1 | O00255 | 1/20 | 0.61 |
| ▸ | NPC1 | O15118 | 1/20 | 0.61 |
| ▸ | CACNA1F | O60840 | 1/20 | 0.61 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.61 |
| ▸ | GMNN | O75496 | 1/20 | 0.61 |
| ▸ | USP2 | O75604 | 1/20 | 0.61 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.61 |
| ▸ | LMNA | P02545 | 1/20 | 0.61 |
| ▸ | TP53 | P04637 | 1/20 | 0.61 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.61 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.61 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.61 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.61 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.61 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.61 |
| ▸ | MAPT | P10636 | 1/20 | 0.61 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.61 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10431015 | 0.82 | FNTA (0.53) | SLC6A15HRH1PTAFR | |
| SCHEMBL10430761 | 0.79 | FNTA (0.51) | SLC6A15HRH1PTAFR | |
| SCHEMBL7669101 | 0.77 | SLC6A15 (0.78) | SLC6A15HRH1MEN1NPC1CACNA1F | |
| SCHEMBL6418027 | 0.77 | HRH1 (0.54) | SLC6A15HRH1MEN1LMNACHRM2 | |
| Loratadine SCHEMBL3862958 | 0.76 | SLC6A15 (1.00) | SLC6A15HRH1MEN1NPC1CACNA1F | |
| Loratadine SCHEMBL4596 | 0.76 | SLC6A15 (1.00) | SLC6A15HRH1MEN1NPC1CACNA1F | |
| Loratadine SCHEMBL29441811 | 0.76 | SLC6A15 (1.00) | SLC6A15HRH1MEN1NPC1CACNA1F | |
| Loratadine SCHEMBL29380223 | 0.76 | SLC6A15 (1.00) | SLC6A15HRH1MEN1NPC1CACNA1F | |
| Loratadine SCHEMBL21529220 | 0.76 | SLC6A15 (0.98) | SLC6A15HRH1MEN1NPC1CACNA1F | |
| Loratadine SCHEMBL21529200 | 0.76 | SLC6A15 (0.98) | SLC6A15HRH1MEN1NPC1CACNA1F |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230323356-A1 | METHOD FOR THE DIAGNOSIS, PROGNOSIS AND TREATMENT OF CANCER METASTASIS | FUNDACIO INST DE RECERCA BIOMEDICA IRB BARCELONA (ES) | 2023-10-12 | — | — | US | disclosed |
| US-11591599-B2 | Method for the diagnosis, prognosis and treatment of cancer metastasis | FUNDACIÓ INSTITUT DE RECERCA BIOMÈDICA (IRB BARCELONA) (ES) | 2023-02-28 | — | — | US | disclosed |
| EP-3272880-B1 | METHOD FOR THE DIAGNOSIS, PROGNOSIS AND TREATMENT OF METASTATIC CANCER | FUNDACIO INST DE RECERCA BIOMEDICA IRB BARCELONA (ES) | 2020-11-25 | — | — | EP | disclosed |
| US-20190309299-A1 | METHOD FOR THE DIAGNOSIS, PROGNOSIS AND TREATMENT OF CANCER METASTASIS | FUNDACIO INSTITUT DE RECERCA BIOMEDICA (IRB BARCELONA) (ES) | 2019-10-10 | — | — | US | disclosed |
| US-20160040247-A1 | METHOD FOR THE DIAGNOSIS, PROGNOSIS, AND TRATMENT OF CANCER METASTASIS | FUNDACIÓ INSTITUT DE RECERCA BIOMÈDICA (IRB BARCELONA) (ES) | 2016-02-11 | — | — | US | disclosed |
| EP-2975138-A2 | METHOD FOR THE DIAGNOSIS, PROGNOSIS AND TREATMENT OF CANCER METASTASIS | Fundació Institut de Recerca Biomèdica (IRB Barcelona) (ES) | 2016-01-20 | — | — | EP | disclosed |
| US-20140314792-A1 | METHOD FOR THE DIAGNOSIS, PROGNOSIS AND TREATMENT OF CANCER METASTASIS | FUNDACIÓ INSTITUT DE RECERCA BIOMÈDICA (IRB BARCELONA) (ES) | 2014-10-23 | — | — | US | disclosed |
| EP-1652524-A1 | DRY SYRUP CONTAINING LORATADINE | SCHERING CORPORATION (US) | 2006-05-03 | — | — | EP | disclosed |
| US-20050112069-A1 | Pharmaceutical composition of a pde4 or pde 3/4 inhibitor and histamine receptor antagonist | NYCOMED GMBH (DE) | 2005-05-26 | — | — | US | disclosed |
| US-20050069590-A1 | Stable suspensions for medicinal dosages | MCBEUK-PPC, INC. | 2005-03-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140314792-A1 | METHOD FOR THE DIAGNOSIS, PROGNOSIS AND TREATMENT OF CANCER METASTASIS | MAFG, RHOXF2, MAFK | SLC6A15 4496/4885HRH1 1455/4885MEN1 683/4885 |
| US-20230323356-A1 | METHOD FOR THE DIAGNOSIS, PROGNOSIS AND TREATMENT OF CANCER METASTASIS | MAFG, RHOXF2, MAFK | SLC6A15 4496/4885HRH1 1455/4885MEN1 683/4885 |
| US-11591599-B2 | Method for the diagnosis, prognosis and treatment of cancer metastasis | MAFG, RHOXF2, MAFK | SLC6A15 4496/4885HRH1 1455/4885MEN1 683/4885 |
| US-20050069590-A1 | Stable suspensions for medicinal dosages | RCC1, PKD1, CCNI | SLC6A15 277/4885HRH1 1071/4885MEN1 584/4885 |
| US-20190309299-A1 | METHOD FOR THE DIAGNOSIS, PROGNOSIS AND TREATMENT OF CANCER METASTASIS | MAFG, RHOXF2, MAFK | SLC6A15 4496/4885HRH1 1455/4885MEN1 683/4885 |
| US-20050112069-A1 | Pharmaceutical composition of a pde4 or pde 3/4 inhibitor and histamine receptor antagonist | HRH4, PDE4A, PDE4B | SLC6A15 3770/4885HRH1 11/4885MEN1 2922/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.